CryoLife

Leading Cardiovascular Surgeons Gather from Around the World to Share Ross Procedure Survival Data, Techniques at 2nd Annual Summit

CryoLife’s Second Annual Surgical Congress for the Ross Procedure to Draw More than 130 Cardiovascular Surgeons from Around the World

CryoLife Receives CE Mark Approval for BioFoam(R) Hemostatic Technology

ATLANTA - - Growing Outcomes Evidence Spurs Renewed Interest in Unique Heart Valve Procedure CryoLife, Inc.

ATLANTA - - The Ross Summit 2009 to focus on new patient data supporting the Ross heart reconstruction procedure and the use of SynerGraft(R) processed human heart valves in the Ross Procedure More than 130 cardiovascular surgeons from approximately 30 countries are scheduled to attend the second annual global Ross Summit, a two-day surgical congress focused on the highly complex Ross Procedure, which is performed on up to 1,500 individuals globally each year -- a number that is expected to increase as survival data become more widely published.

MORE..

Older News

ATLANTA - CryoLife, Inc., (NYSE: CRY) an implantable biological medical device and cardiovascular tissue processing company, today announced it has received CE mark approval for its BioFoam(R) Surgical Matrix (BioFoam).

MORE..